Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, January 29, 2020
GeoVax Labs and BravoVax announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus (known as 2019-nCoV).
read more
Monday, December 30, 2019
GenScript has announced it signed a strategic collaboration agreement with Selecxine, a Korean biotech company dedicated to novel therapeutics for immuno-oncology.
read more
GenScript Biotech Corporation along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated announced that they have entered into a strategic licensing agreement for Ligand's OmniAb® Platform, a multi-species antibody discovery...
read more
Genovac, a contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies for therapeutic, diagnostic and research market segments, and ENPICOM, a bioinformatics software engineering company, ...
read more
Genomma Lab has announced the Mexican Federal COFEPRIS has granted the Sanitary License which permits the Company's new manufacturing facility to begin operations.
read more
Monday, December 06, 2021
Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has officially opened its new process development and ...
read more
Wednesday, October 12, 2022
Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral and retroviral vector manufacturing, has completed another expansion phase at its viral vector process development and cGMP vector ...
read more
Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has broken ground on a new multiphase master...
read more
Tuesday, January 25, 2022
Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, GMP vector production and analytical testing services, has appointed Laura Jacanin as Senior Director of ...
read more
Thursday, December 01, 2022
Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral and retroviral vector manufacturing, continues to scale and expand its commercial operations with the appointment of Jeff Whitmore ...
read more
Wednesday, September 22, 2021
GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, announced that it has contracted Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), to ...
read more
Ajinomoto Bio-Pharma Services announced GeneDesign has joined the global organization.
read more
Tuesday, January 07, 2014
GE (NYSE:GE) and Thermo Fisher Scientific (NYSE:TMO) announced today that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses for ...
read more
Friday, September 13, 2019
GE Healthcare and Germfree are joining expertise to develop a fully integrated, expandable manufacturing solution for emerging biotherapeutics, including gene therapy.
read more
Wednesday, October 06, 2021
The Gates Biomanufacturing Facility (GBF) announced a continued strategic agreement with Nkarta, Inc. to manufacture clinical supply of therapeutic Natural Killer (NK) cells. As part of this collaboration, GBF will continue to manufacture NKX101, ...
read more